MARKET

ANGO

ANGO

Angiodynamics
NASDAQ
7.65
+0.14
+1.86%
After Hours: 7.50 -0.15 -1.96% 16:57 07/26 EDT
OPEN
7.51
PREV CLOSE
7.51
HIGH
7.73
LOW
7.47
VOLUME
614.70K
TURNOVER
0
52 WEEK HIGH
9.77
52 WEEK LOW
5.26
MARKET CAP
306.42M
P/E (TTM)
-1.6674
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ANGO last week (0715-0719)?
Weekly Report · 4d ago
AngioDynamics, Inc. (NASDAQ:ANGO) Just Released Its Annual Results And Analysts Are Updating Their Estimates
AngioDynamics, Inc. (NASDAQ:ANGO) reported revenue of US$304m ahead of expectations. The company's stock price is up 13% to US$6.95 following its yearly results. Analysts have not changed their forecasts for the company's revenue for next year. However, the company is expected to lag the wider industry in the coming years.
Simply Wall St · 07/19 11:54
Insiders Buying AngioDynamics Might Wish They Invested More, Stock Gains 32%
AngioDynamics, Inc. Insiders bought US$67k worth of shares in the last year. The company's share price rose 32% last week. The CEO, President & Director James Clemmer made the biggest insider purchase. Angiodynamics insiders own 2.9% of the company. The insider sale of shares was at a price close to the current price of US$7.40.
Simply Wall St · 07/18 11:08
Improved Revenues Required Before AngioDynamics, Inc. (NASDAQ:ANGO) Stock's 26% Jump Looks Justified
The AngioDynamics, Inc. Share price has risen 26% over the last month. The stock is still down 17% in the last year. The company's price-to-sales ratio of 1x is lower than the rest of the Medical Equipment industry. However, the company's revenue growth has been going backwards recently. The underwhelming revenue outlook is a major contributor to the low P/S ratio.
Simply Wall St · 07/18 11:06
AngioDynamics Is Maintained at Buy by Canaccord Genuity
Dow Jones · 07/17 19:34
AngioDynamics Price Target Cut to $13.00/Share From $18.00 by Canaccord Genuity
Dow Jones · 07/17 19:34
Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $13
Benzinga · 07/17 19:23
AngioDynamics: Lumpy Progress Is Still Progress
AngioDynamics stock reacted positively to fiscal Q4 results, up over 25% in a day. The company saw 8% sequential revenue growth and 14% growth from the Med Tech portfolio. Execution remains the key to the company's success. AngioDynamicics is a name worth considering after years of disappointing results.
Seeking Alpha · 07/17 19:16
More
About ANGO
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Webull offers AngioDynamics, Inc. stock information, including NASDAQ: ANGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANGO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANGO stock methods without spending real money on the virtual paper trading platform.